United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M Estimate
Share
Why It Matters
United Therapeutics made more money per share than expected, but didn't sell as much stuff overall as people thought they would. When a company's profits beat but sales miss, it means they're managing costs well—but watch if sales growth catches up next time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.